Search

Sep 5, 2024
Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest
CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector...